These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 12388634)

  • 21. Comparative effects of interferon alpha-2b and pegylated interferon alpha-2b on menstrual cycles and ovarian hormones in cynomolgus monkeys.
    Enright BP; Compton DR; Collins N; Davis T; McIntyre BS
    Birth Defects Res B Dev Reprod Toxicol; 2009 Feb; 86(1):29-39. PubMed ID: 19243028
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Safety pharmacology, toxicology and pharmacokinetic assessment of recombinant human omega-interferon produced from CHO-SS cells.
    Buckwold VE; Lang W; Scribner C; Blanchett D; Alessi T; Langecker P
    Basic Clin Pharmacol Toxicol; 2006 Jul; 99(1):62-70. PubMed ID: 16867173
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacokinetics and pharmacodynamics of recombinant human interferon-beta in healthy male volunteers.
    Salmon P; Le Cotonnec JY; Galazka A; Abdul-Ahad A; Darragh A
    J Interferon Cytokine Res; 1996 Oct; 16(10):759-64. PubMed ID: 8910759
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Circumventing the heterogeneity and instability of human serum albumin-interferon-alpha2b fusion protein by altering its orientation.
    Zhao HL; Xue C; Wang Y; Li XY; Xiong XH; Yao XQ; Liu ZM
    J Biotechnol; 2007 Sep; 131(3):245-52. PubMed ID: 17698234
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Calcium Phosphate Particles as Pulmonary Delivery System for Interferon-α in Mice.
    Morçöl T; Weidner JM; Mehta A; Bell SJD; Block T
    AAPS PharmSciTech; 2018 Jan; 19(1):395-412. PubMed ID: 28752471
    [TBL] [Abstract][Full Text] [Related]  

  • 26. In vivo sustained dermal delivery and pharmacokinetics of interferon alpha in biphasic vesicles after topical application.
    King M; Kumar P; Michel D; Batta R; Foldvari M
    Eur J Pharm Biopharm; 2013 Aug; 84(3):532-9. PubMed ID: 23500117
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Improved pharmacokinetic properties of a polyethylene glycol-modified form of interferon-beta-1a with preserved in vitro bioactivity.
    Pepinsky RB; LePage DJ; Gill A; Chakraborty A; Vaidyanathan S; Green M; Baker DP; Whalley E; Hochman PS; Martin P
    J Pharmacol Exp Ther; 2001 Jun; 297(3):1059-66. PubMed ID: 11356929
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Extravascular administration of interferon alfa-N3 increases serum exposure and 2-5(A) synthetase activity.
    Sturgill MG; Rashidbaigi A; Liao MJ; Zhao XX; Hua J; Trout R; Knill JR; Grasing KW
    J Clin Pharmacol; 2000 Jun; 40(6):606-15. PubMed ID: 10868311
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacokinetic study of a human recombinant interferon (Re-IFN-alpha A) in cynomolgus monkeys by 2'-5' oligoadenylate synthetase assay.
    Bannai H; Tatsumi M; Kohase M; Onishi E; Yamazaki S
    Jpn J Med Sci Biol; 1985 Jun; 38(3):113-24. PubMed ID: 2999483
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacokinetics of natural human IFN-alpha in hemodialysis patients.
    Gotoh A; Hara I; Fujisawa M; Okada H; Arakawa S; Kudo S; Obe T; Maruyama S; Sakai R; Kamidono S
    J Interferon Cytokine Res; 1999 Oct; 19(10):1117-23. PubMed ID: 10547151
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of pharmacokinetic behaviors of two human interferons (Lb-IFN-alpha and Re-IFN-alpha A) in cynomolgus monkeys by 2'-5' oligoadenylate synthetase assay.
    Bannai H
    Jpn J Med Sci Biol; 1986; 39(5-6):185-98. PubMed ID: 3599526
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prolonging the half-life of human interferon-alpha 2 in circulation: Design, preparation, and analysis of (2-sulfo-9-fluorenylmethoxycarbonyl)7- interferon-alpha 2.
    Shechter Y; Preciado-Patt L; Schreiber G; Fridkin M
    Proc Natl Acad Sci U S A; 2001 Jan; 98(3):1212-7. PubMed ID: 11158619
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Balancing the pharmacokinetics and pharmacodynamics of interferon-α2b and human serum albumin fusion protein by proteolytic or reductive cleavage increases its in vivo therapeutic efficacy.
    Zhao HL; Xue C; Du JL; Ren M; Xia S; Liu ZM
    Mol Pharm; 2012 Mar; 9(3):664-70. PubMed ID: 22224503
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Intact bioactivities and improved pharmacokinetic of the SL335-IFN-β-1a fusion protein that created by genetic fusion of SL335, a human anti-serum albumin fab, and human interferon-β.
    Ji SI; Park JH; You HG; Chi HJ; Bang YW; Cha SH
    Immunol Lett; 2019 Mar; 207():46-55. PubMed ID: 30684504
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Albutropin: a growth hormone-albumin fusion with improved pharmacokinetics and pharmacodynamics in rats and monkeys.
    Osborn BL; Sekut L; Corcoran M; Poortman C; Sturm B; Chen G; Mather D; Lin HL; Parry TJ
    Eur J Pharmacol; 2002 Dec; 456(1-3):149-58. PubMed ID: 12450581
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Use of an indirect pharmacodynamic stimulation model of MX protein induction to compare in vivo activity of interferon alfa-2a and a polyethylene glycol-modified derivative in healthy subjects.
    Nieforth KA; Nadeau R; Patel IH; Mould D
    Clin Pharmacol Ther; 1996 Jun; 59(6):636-46. PubMed ID: 8681488
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacokinetics, pharmacodynamics, and hepatitis C viral kinetics during antiviral therapy: the null responder.
    Di Bisceglie AM; Fan X; Chambers T; Strinko J
    J Med Virol; 2006 Apr; 78(4):446-51. PubMed ID: 16566033
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Expression in Pichia pastoris and properties of human serum albumin-interferon alpha2b chimera].
    Chang SH; Gong X; Yang ZY; Wang TY; Ma GC; Ma QJ; Wu J
    Sheng Wu Gong Cheng Xue Bao; 2006 Mar; 22(2):173-9. PubMed ID: 16607939
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Relationship between 24-hour rhythm in antiviral effect of interferon-beta and interferon-alpha/beta receptor expression in mice.
    Takane H; Ohdo S; Baba R; Koyanagi S; Yukawa E; Higuchi S
    Jpn J Pharmacol; 2002 Dec; 90(4):304-12. PubMed ID: 12501006
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Treating cancer with PEG Intron: pharmacokinetic profile and dosing guidelines for an improved interferon-alpha-2b formulation.
    Bukowski RM; Tendler C; Cutler D; Rose E; Laughlin MM; Statkevich P
    Cancer; 2002 Jul; 95(2):389-96. PubMed ID: 12124839
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.